Search

Displaying results 4401 - 4410 of 9887 in total
  1. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    Non-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do not provide antiviral protection against the … A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient.

  2. Drug

    Elbasvir

    go.drugbank.com/drugs/DB11574
    Approved

    [L10253] Elbasvir and [grazoprevir] are used with or without [ribavirin] with the intent to cure, or achieve a sustained virologic response (SVR), and have been shown to achieve a SVR between 94% and 97% … Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly.

  3. Drug

    Voclosporin

    go.drugbank.com/drugs/DB11693
    ApprovedInvestigational

    LN is a significant cause of renal failure, morbidity, and death in patients with SLE. … Lupus nephritis (LN) is a type of glomerulonephritis occurring in patients with systemic lupus erythematosus (SLE).

  4. Drug

    Basic Fibroblast Growth Factor

    go.drugbank.com/drugs/DB14131
    Investigational

    Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. … Basic Fibroblast Growth Factor (bFGF) is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of physiologic angiogenesis.

  5. Drug

    Ormeloxifene

    go.drugbank.com/drugs/DB13310
    Experimental

    [A251450,A251460] Ormeloxifene is marketed in India as a racemic mixture of the l- (levormeloxifene) and d-isomers (d-ormeloxifene) of _trans_-ormeloxifene. … Ormeloxifene is a third-generation selective estrogen receptor (ER) modulator.

  6. Drug

    MUC1 Dendritic Cell Vaccine

    go.drugbank.com/drugs/DB05477
    Investigational

    Dendritic Cell (DC) Therapy is a newly emerging and potent form of immune therapy that amplifies the actions of the body's own immune system to help fight cancer, AIDS and other serious conditions. … These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.

  7. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.

  8. Drug

    Procainamide

    go.drugbank.com/drugs/DB01035
    Approved

    A derivative of procaine with less CNS action.

    Categories: Antiarrhythmics, Class Ia, OCT2 Substrates with a Narrow Therapeutic Index
  9. Drug

    Peginterferon lambda-1a

    go.drugbank.com/drugs/DB14767
    Investigational

    Peginterferon lambda-1a is under investigation in clinical trial NCT01754974 (Safety and Efficacy Study of Peginterferon Lambda-1a vs. … Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C).

    Synonyms: Peginterferon lambda-1a
  10. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973] … [A260192] As a result, the main clinical manifestation of myasthenia gravis is easily fatigable or persistent muscle weakness.